Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CNR2 | P34972 | 8/20 | 0.60 |
| ▸ | CNR1 | P21554 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7191689 | 0.90 | CNR2 (0.53) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL7932704 | 0.89 | CA12 (0.49) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL7186933 | 0.89 | FEN1 (0.51) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL7190690 | 0.87 | CNR2 (0.54) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL7187891 | 0.87 | CA12 (0.47) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL7191310 | 0.87 | KDM4E (0.50) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL7192077 | 0.87 | CA12 (0.47) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL7190379 | 0.87 | PTPN1 (0.54) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL7177997 | 0.86 | CA12 (0.46) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL7185378 | 0.85 | CA12 (0.65) | CA12CA1CA2CA9CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012095388-A2 | COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE | Universität Zürich (CH) | 2012-07-19 | — | — | WO | claimed |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | claimed |
| WO-2006129134-A1 | SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV INFECTION THERAPEUTIC AGENTS | BIOALLIANCE PHARMA (FR) | 2006-12-07 | — | — | WO | claimed |
| EP-1083897-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2003-01-02 | — | — | EP | claimed |
| US-6306891-B1 | INHIBITORS OF HIV INTEGRASE AND INHIBITORS OF HIV REPLICATION. THESE COMPOUNDS ARE USEFUL IN THE PREVENTION OR TREATMENT OF INFECTION BY HIV TREATMENT OF AIDS, EITHER AS COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS | MERCK & CO., INC. | 2001-10-23 | — | — | US | claimed |
| EP-1083897-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| WO-1999062513-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-13 | — | — | US | disclosed |
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-7250421-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250421-B2 | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| WO-2006129134-A1 | SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV INFECTION THERAPEUTIC AGENTS | BIOALLIANCE PHARMA (FR) | 2006-12-07 | — | — | WO | disclosed |
| EP-1083897-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6306891-B1 | INHIBITORS OF HIV INTEGRASE AND INHIBITORS OF HIV REPLICATION. THESE COMPOUNDS ARE USEFUL IN THE PREVENTION OR TREATMENT OF INFECTION BY HIV TREATMENT OF AIDS, EITHER AS COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1083897-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062513-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | PCSK9, HMGCR, PCSK7 | CA12 3457/4885CA1 3610/4885CA2 2553/4885 |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | CA12 4674/4885CA1 3873/4885CA2 4061/4885 |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | CA12 727/4885CA1 2223/4885CA2 1070/4885 |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CTSL, CDKL1, QTRT2 | CA12 4562/4885CA1 4511/4885CA2 3941/4885 |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | ROS1, NOX4, NOX5 | CA12 4772/4885CA1 4764/4885CA2 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.